Analysts estimate that Lineage Cell Therapeutics will report an earnings per share (EPS) of $-0.02.
Lineage Cell Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Overview of Past Earnings
Last quarter the company beat EPS by $0.01, which was followed by a 2.55% drop in the share price the next day.
Here's a look at Lineage Cell Therapeutics's past performance and the resulting price change:
Quarter
Q1 2025
Q4 2024
Q3 2024
Q2 2024
EPS Estimate
-0.03
-0.03
-0.03
-0.04
EPS Actual
-0.02
-0.02
-0.02
-0.03
Price Change %
-3.0%
0.0%
-2.0%
3.0%
Market Performance of Lineage Cell Therapeutics's Stock
Shares of Lineage Cell Therapeutics were trading at $0.9844 as of August 08. Over the last 52-week period, shares are up 20.57%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.
Analyst Opinions on Lineage Cell Therapeutics
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Lineage Cell Therapeutics.
The consensus rating for Lineage Cell Therapeutics is Buy, ...
